Hydrochloric Acid

Hydrochloric Acid

SCHEMBL314036

CCCCCCCCC=CCCCCCCCC[N+](C)(CCO)CCO.[Cl-]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 1/20 0.43
SLC6A2 known ✓ P23975 1/20 0.43
DNM1 Q05193 3/20 0.52
MMP2 P08253 2/20 0.49
PSMD14 O00487 1/20 0.49
PLA2G1B P04054 1/20 0.49
RAD52 P43351 1/20 0.49
ATG4B Q9Y4P1 1/20 0.49
FAAH O00519 4/20 0.44
TRPV1 Q8NER1 1/20 0.44
TERT O14746 3/20 0.43
CYP1A2 P05177 2/20 0.43
MAPT P10636 2/20 0.43
CYP2C19 P33261 2/20 0.43
BLM P54132 2/20 0.43
HSD17B10 Q99714 2/20 0.43
FABP4 P15090 2/20 0.43
PTPN1 P18031 2/20 0.43
PPARG P37231 2/20 0.43
KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7193104 1.00 DNM1 (0.52) DNM1MMP2PSMD14PLA2G1BRAD52
Hydrochloric Acid SCHEMBL7193100 1.00 DNM1 (0.52) DNM1MMP2PSMD14PLA2G1BRAD52
Hydrochloric Acid SCHEMBL313936 1.00 DNM1 (0.52) DNM1MMP2PSMD14PLA2G1BRAD52
Hydrochloric Acid SCHEMBL314034 1.00 DNM1 (0.52) DNM1MMP2PSMD14PLA2G1BRAD52
Hydrochloric Acid SCHEMBL313938 1.00 DNM1 (0.52) DNM1MMP2PSMD14PLA2G1BRAD52
SCHEMBL4260134 0.98 DNM1 (0.53) DNM1MMP2PSMD14PLA2G1BRAD52
SCHEMBL417771 0.98 DNM1 (0.53) DNM1MMP2PSMD14PLA2G1BRAD52
SCHEMBL417769 0.98 DNM1 (0.53) DNM1MMP2PSMD14PLA2G1BRAD52
SCHEMBL7783882 0.98 DNM1 (0.53) DNM1MMP2PSMD14PLA2G1BRAD52
SCHEMBL4260132 0.98 DNM1 (0.53) DNM1MMP2PSMD14PLA2G1BRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250043208-A1 LUBRICIOUS SURFACES, SYSTEMS AND METHODS FOR MAKING THE SAME LiquiGlide Inc. 2025-02-06 US claimed
US-20220282177-A1 LUBRICIOUS SURFACES, SYSTEMS AND METHOD FOR MAKING THE SAME LiquiGlide Inc. 2022-09-08 US claimed
US-20210198559-A1 Viscoelastic-Surfactant Fracturing Fluids Having Oxidizer SAUDI ARABIAN OIL COMPANY (SA) 2021-07-01 US claimed
US-8633261-B2 Polymer composites having particles with mixed organic modifications THE UNIVERSITY OF QUEENSLAND (AU) 2014-01-21 US claimed
US-8361300-B2 Cost effective ionic liquids such as Choline Saccharinate to electroplate chromium, aluminium, or copper; improved surface finish, with greatly diminished micro-cracking, thinner with good corrosion resistance; environmentally friendly AKZO NOBEL N.V. (NL) 2013-01-29 US claimed
US-20110060072-A1 POLYMER COMPOSITES HAVING PARTICLES WITH MIXED ORGANIC MODIFICATIONS THE UNIVERSITY OF QUEENSLAND (AU) 2011-03-10 US claimed
EP-2271707-A1 POLYMER COMPOSITES HAVING PARTICLES WITH MIXED ORGANIC MODIFICATIONS The University of Queensland (AU) 2011-01-12 EP claimed
EP-2171131-B1 METHOD TO ELECTRODEPOSIT METALS USING IONIC LIQUIDS IN THE PRESENCE OF AN ADDITIVE AKZO NOBEL NV (NL) 2010-12-29 EP claimed
US-20100252446-A1 Method to Electrodeposit Metals Using Ionic Liquids in the Presence of an Additive AKZO NOBEL N.V. (NL) 2010-10-07 US claimed
EP-2171131-A1 METHOD TO ELECTRODEPOSIT METALS USING IONIC LIQUIDS IN THE PRESENCE OF AN ADDITIVE Akzo Nobel N.V. (NL) 2010-04-07 EP claimed
US-20020155970-A1 Fabric care compositions UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2002-10-24 US claimed
WO-2001078670-A2 PHASE-SEPARATED RINSE-OFF HAIR COLORING/CONDITIONING PRODUCTS THE PROCTER & GAMBLE COMPANY (US) 2001-10-25 WO claimed
WO-2001051767-A2 ADDITION OF SOLIDS TO GENERATE VISCOSITY DOWNHOLE SCHLUMBERGER TECHNOLOGY CORPORATION (US) 2001-07-19 WO claimed
US-5547661-A MIXTURE WITH A CROSSLINKER, SURFACTANT AND CARRIER HELENE CURTIS, INC. (US) 1996-08-20 US claimed
US-5385586-A Increasing the crystallization of alumina trihydrate by adding a cationic surfactant quaternary ammonium compound to inhibit the precipitation of sodium oxalate NALCO CHEMICAL COMPANY (US) 1995-01-31 US claimed
EP-0296995-B1 Concentrated softening compositions COTELLE SA (FR) 1994-05-04 EP claimed
EP-0483095-A2 Improved formulations MONSANTO COMPANY (US) 1992-04-29 EP claimed
EP-0324261-A1 Production of L-ascorbic acid from 2-keto-L-gulonic acid with an acid catalyst and a lipophilic surfactant having a low hydrophilic: lipophilic balance under substantially anhydrous conditions PFIZER INC. (US) 1989-07-19 EP claimed
EP-0142028-B1 REVERSIBLE PHASE CHANGE COMPOSITION FOR STORING THERMAL ENERGY THE DOW CHEMICAL COMPANY (US) 1987-08-05 EP claimed
US-4585572-A CATIONIC SURFACTANT THICKENER THE DOW CHEMICAL COMPANY (US) 1986-04-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060072-A1 POLYMER COMPOSITES HAVING PARTICLES WITH MIXED ORGANIC MODIFICATIONS PUF60, PCBP1, LCP1 CHRM1 1134/4885SLC6A2 4327/4885DNM1 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.